IGM Biosciences and Sanofi have revised the previous exclusive worldwide agreement to solely develop 3 immunology/inflammation targets. IGM will keep the worldwide rights to its technology related to the oncology targets nominated by Sanofi
Under the agreement, IGM will be responsible for the research & development of the targets covering the cost of P-I study for up to two constructs per target. Sanofi will handle further development & commercialization activities & related costs
IGM is entitled to receive a total of ~$1,065M as development, regulatory & commercial milestones per target plus tiered high single-digit to low-teen sales-based royalties
Ref: IGM Biosciences | Image: IGM Biosciences
Related News:- IGM Biosciences Entered into a Clinical Collaboration Agreement with ADC to Evaluate Imvotamab (IGM-2323) + Zynlonta (loncastuximab tesirine-lpyl) for B Cell Non-Hodgkin’s Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
